CORT Alert: FDA Rejection Sparks Class Action Concerns!

Corcept Therapeutics (NASDAQ: CORT) – a biotech focused on cortisol-modulating drugs – has come under intense scrutiny after a major regulatory setback. On December 31, 2025, the FDA issued a surprise Complete Response Letter (CRL) rejecting Corcept’s New Drug Application for its lead candidate relacorilant in hypercortisolism (www.prnewswire.com). The news halved CORT’s share price (from ~$70 to ~$35) in one day (www.prnewswire.com), erasing about $2.5 billion in market value. The FDA concluded it “could not arrive at a favorable benefit-risk assessment” for relacorilant due to “insufficient” evidence of efficacy (www.prnewswire.com). In the fallout, shareholders filed a securities class action alleging Corcept’s management hid repeated FDA warnings about relacorilant’s trial flaws (www.prnewswire.com). This report examines Corcept’s fundamentals – from dividend policy and leverage to valuation – and analyzes the risks, red flags, and open questions now facing the company in light of these developments.

Company & Pipeline Overview

Corcept is a commercial-stage pharma company specializing in drugs that modulate the hormone cortisol. Its sole marketed product is Korlym (mifepristone) for Cushing’s syndrome (hypercortisolism). Korlym has been a strong revenue generator – net product sales were $761.4 million in 2025, up 13% from $675 million in 2024 (www.sec.gov). This growth was volume-driven, reflecting robust demand for cortisol-modulating therapy in Cushing’s patients. Korlym’s contribution is critical: Corcept’s operations and R&D are almost entirely funded by Korlym’s cash flows (www.sec.gov) (www.sec.gov). However, the company’s heavy reliance on one drug is a double-edged sword. Generic competition is now a pressing threat – Corcept’s key patents for Korlym were invalidated, and Teva launched a generic Korlym in January 2024 after a court ruled Teva’s version does not infringe Corcept’s patents (www.sec.gov). Corcept managed to sustain sales despite Teva’s entry, partly via its own authorized generic distribution, but the legal defeat on appeal in Feb 2026 removes any remaining patent shield (www.sec.gov). With multiple generics (Teva, Sun, Hikma) poised to enter once approved (www.sec.gov), Korlym’s future revenues are at serious risk.

Corcept’s pipeline aims to diversify beyond Korlym. The centerpiece was relacorilant, a next-generation cortisol modulator. Relacorilant was tested in the Phase 3 GRACE trial for hypercortisolism, but according to the class action, FDA officials had warned the trial’s design/data were inadequate for approval (www.prnewswire.com). Corcept nevertheless submitted an NDA in 2025, only to have the FDA issue a CRL (i.e. rejection) on Dec. 31, 2025 (www.prnewswire.com). This high-profile failure leaves Corcept without a near-term replacement for Korlym in Cushing’s syndrome. On a more positive note, relacorilant is also being studied in oncology: the FDA has accepted an NDA for relacorilant in platinum-resistant ovarian cancer (Phase 3 ROSELLA trial), with a PDUFA decision date set for July 11, 2026 (ir.corcept.com) (ir.corcept.com). Positive trial data in ovarian cancer were the basis for this application (ir.corcept.com). Other pipeline projects include miricorilant (a cortisol modulator in trials for liver disease/NASH (ir.corcept.com)) and additional early-stage candidates targeting oncology and metabolic disorders (www.sec.gov) (www.sec.gov). In short, Corcept is attempting to pivot to new indications, but its pipeline’s success is uncertain – and now absolutely crucial – given the one-two punch of a failed relacorilant approval and looming generic erosion of Korlym.

Dividend Policy & Shareholder Returns

Corcept does not pay a dividend and has never paid one in its history (www.sec.gov) (www.sec.gov). The company explicitly states it has “never declared or paid any dividends” and does not anticipate initiating dividends in the foreseeable future (www.sec.gov). This policy is typical for growth-focused biotechs, which generally reinvest cash into R&D rather than distribute it. Instead of dividends, Corcept has returned capital to shareholders via stock buybacks. In 2023, the company conducted a large tender offer, repurchasing 6.6 million shares at $22 each ( ~$145 million total) (www.sec.gov). It also initiated a $200 million open-market repurchase program in 2025. Under this program, Corcept bought back 2.6 million shares in 2025 at an average price of $66.71, for a total of $172.9 million spent (www.sec.gov). These repurchases reflect management’s confidence (the 2025 buybacks occurred when CORT stock was near all-time highs) and have moderately reduced the share count. However, in hindsight the 2025 buybacks at ~$67 look costly given the stock collapse to the mid-$30s after the FDA rejection. Going forward, with cash needed to weather potential revenue declines and fund pipeline trials, Corcept may be more constrained in returning cash to shareholders.

Yield: Since there is no dividend, CORT’s dividend yield is 0%. The shareholder “yield” has come instead from buybacks. In 2025, buyback spending of $172.9M was about 4.6% of Corcept’s year-end market cap (~$3.8B at $35/share), effectively a 4.6% shareholder yield via repurchases. Investors should note that capital return policies could be revisited if business conditions tighten – e.g. the company might pause buybacks to conserve cash should Korlym sales erode faster than expected (Corcept had $532.4 million in cash and marketable securities on hand at 2025’s end (www.sec.gov), a buffer that could fund R&D and possible legal costs).

Leverage, Debt Maturities & Coverage

Corcept’s balance sheet is debt-free, affording it significant financial flexibility. The company carries no long-term debt – an unusual but positive position for a mid-cap biotech. There are also no outstanding credit facilities or substantial loan obligations reported. Consequently, Corcept has no debt maturities upcoming that investors need to worry about. Instead of debt financing, Corcept has relied on internal cash generation and equity when needed. As of December 31, 2025, Corcept held $532.4 million in cash, equivalents and marketable securities (www.sec.gov), and its total liabilities consisted mainly of accounts payable, accruals, and lease obligations (typical operational liabilities, not bank debt). This strong net cash position means Corcept is not exposed to refinancing or interest rate risk on debt – an important strength given current capital market volatility.

Coverage: With zero financial debt, traditional interest coverage ratios are a moot point for Corcept. The company in fact earns interest income (about $21.7 million in 2025 from investing its cash reserves) (www.sec.gov) rather than paying interest expense. Corcept’s operating earnings easily cover its modest fixed obligations (like office leases), and the absence of interest expense leaves EBIT coverage of interest essentially infinite. Another lens to consider is cash flow coverage of the company’s needs. In 2025, Corcept generated $142.0 million in operating cash flow (www.sec.gov), comfortably funding its $33 million in R&D increase and other operating costs (and partially funding the $172.9M in buybacks, supplemented by cash on hand) (www.sec.gov) (www.sec.gov). Even if Korlym’s cash flows decline with generic entry, Corcept’s lack of debt means it won’t face creditor pressure. In summary, leverage is not a near-term risk for Corcept – its financial capacity to cover obligations remains solid, buying it time to invest in new products. The key coverage concern is not interest payments, but whether operational cash flow will continue to cover the company’s heavy R&D and potential legal liabilities in coming years if core revenues drop sharply.

Valuation and Financial Metrics

At the current trading range (~$33–$35 post-drop), Corcept’s valuation reflects both its past profitability and the uncertainty of its future earnings. Based on 2025 results, CORT now trades at roughly 42× trailing earnings (2025 diluted EPS was $0.82 (www.sec.gov) and stock price ~$34–$35). This P/E ~40+ is elevated relative to the broad market, especially considering that 2025 earnings ($99.7M net income) were down from 2024 (www.sec.gov). However, a trailing P/E is of limited relevance here – investors are really pricing in a sharp earnings decline ahead. If Korlym’s sales erode (due to generics) and relacorilant remains unapproved for Cushing’s, Corcept’s future EPS could fall significantly, making the forward P/E much higher than 40. In effect, the market is discounting a contraction in profits but still assigning some value to the pipeline’s potential (e.g. the ovarian cancer indication and other trials).

Other metrics underscore a shifting valuation framework. Corcept’s enterprise value (EV) is about ~$3.3 billion (market cap ~$3.7B minus ~$0.4B net cash). That yields an EV/Revenue of ~4.3× using 2025 sales of $761M, or EV/EBITDA of roughly 20× (Corcept’s 2025 operating margin was healthy). These multiples are not cheap for a company facing a looming loss of exclusivity; by comparison, large pharma companies trade at ~4× sales on stable portfolios, but often <10× EV/EBITDA. The premium in Corcept’s multiple likely reflects the optionality of its pipeline. Before the FDA rejection, CORT stock had run up dramatically – it was trading at ~$70 (over 85× trailing earnings) on optimism for relacorilant and continued growth (www.prnewswire.com) (www.sec.gov). The 50% crash on the CRL news (www.prnewswire.com) essentially wiped out the speculative “pipeline premium” in the stock. Now, at ~$35, the valuation can be seen as roughly the value of Korlym’s cash flows over the next few years (before generics fully bite), plus a heavily discounted chance that Corcept develops new revenue streams.

Comparables: Pure-play comps are limited – few biotech companies have Corcept’s mix of one profitable orphan drug and a pipeline. One reference point is the broader biotech sector multiples: many mid-cap biotechs with no near-term profit trade on EV/sales of 2–5× if they have a marketed product, and on hope value otherwise. Corcept at ~4× sales is in the upper range, justified only if it can sustain revenue or replace it via pipeline. If Korlym sales plummet (say, cut in half or more within a couple of years), that sales multiple would spike unless the stock falls further. Price to free cash flow is another lens: Corcept’s 2025 operating cash flow was $142M (www.sec.gov), so price/OCF is ~26× – again reflecting the market’s expectation of a smaller future cash flow base. In sum, CORT’s valuation is high for a contracting business, and hinges on pipeline execution. Investors are paying for the company’s strong current financials (cash-rich, profitable) but also taking on substantial risk that those metrics deteriorate. The recent class action and FDA setback amplify uncertainty, which often merits a valuation discount; it remains to be seen if the current ~$3.5B valuation fully accounts for the headwinds ahead.

Risks and Red Flags

Corcept faces heightened risks on multiple fronts following the FDA rejection and patent loss. Key risk factors and red flags include:

– Pipeline Failure & Regulatory Risk: The FDA’s CRL for relacorilant in Cushing’s syndrome is a major blow. It indicates the agency found the Phase 3 data fundamentally insufficient (www.prnewswire.com). Management had been upbeat about relacorilant’s prospects, even as the FDA reportedly cautioned them in 2024-25 about shortcomings (www.prnewswire.com). The disconnect raises a red flag about management’s judgment and communication. It also means Corcept has no guaranteed successor to Korlym in its core indication. The company may need to run new trials (costly and time-consuming) to address the FDA’s concerns, or risk writing off years of development. Upcoming regulatory events carry risk too – e.g. the July 2026 FDA decision on relacorilant in ovarian cancer will be pivotal. A second FDA rejection (in oncology) would compound doubts about Corcept’s R&D approach.

– Generic Erosion of Korlym: The patent cliff is arriving faster than expected. A federal court ruled that Teva’s Korlym generic did not infringe Corcept’s patents, a decision affirmed on appeal (www.sec.gov). Teva already launched its generic in 2024 (www.sec.gov), and other generics (Sun, Hikma) have settlement terms allowing entry once Teva is in the market (www.sec.gov). This opens the door to accelerating competition. Korlym’s $761M revenue in 2025 could decline sharply as generics gain traction, either through loss of market share or forced price reductions (payers will demand discounts). Corcept’s own authorized generic and specialty pharmacy strategy mitigated some impact initially, but an extended multigeneric scenario will inevitably shrink sales. A decline in Korlym revenue not only hits earnings but could constrain funding for Corcept’s pipeline programs. It’s worth noting that Corcept had guided for $800–$850M Korlym revenue in 2025 (briefglance.com) (briefglance.com) – actual sales came in below that, partly due to a specialty pharmacy supply shortfall (www.sec.gov), hinting at how delicate sustaining growth has become. The permanent entry of generics is a fundamental risk to Corcept’s business model.

– Legal and Governance Risks: The fallout from relacorilant’s failure includes a shareholder class action lawsuit (Allegheny County Employees’ Retirement System v. Corcept) alleging that management misled investors about FDA feedback and the drug’s prospects (www.prnewswire.com) (www.sec.gov). Specifically, the complaint claims Corcept concealed FDA’s efficacy concerns and continued to tout positive trial results (www.prnewswire.com). If these allegations are proven, it would imply serious governance lapses – undermining investor trust in management’s disclosures. Even if the case is eventually settled or dismissed, it will consume management attention and legal resources. Separately, Corcept is also embroiled in an antitrust lawsuit filed by Teva, accusing Corcept of unfair practices in how it distributed Korlym and its authorized generic (www.sec.gov) (www.sec.gov). While Corcept got some of Teva’s claims dismissed in court (www.sec.gov), the case is ongoing. An adverse outcome could impose fines or force changes in Corcept’s business practices. These legal battles present additional risk factors beyond the core operational challenges – and they spotlight potential red flags in how the company has conducted itself against competition.

– Concentration & Competition: Corcept’s dependence on a single product (Korlym) and a single mechanism (cortisol modulation) concentrates its risk. In Cushing’s syndrome, Korlym’s dominance will be challenged not just by generics but by alternative therapies. Newer treatments like Recorlev (levoketoconazole) have entered the market, and other drugs (pasireotide, cabergoline) compete in certain patient segments (www.sec.gov) (www.sec.gov). Doctors and payers may shift to these alternatives if Korlym becomes less accessible or if generics drive down its price. Moreover, public controversy around mifepristone (Korlym’s active ingredient, also used as an abortion pill) poses a reputational and regulatory risk – legislation or stigma affecting mifepristone could indirectly impact Korlym’s use (www.sec.gov). On the pipeline side, competition is intense in oncology and metabolic diseases; for instance, the market for platinum-resistant ovarian cancer has multiple trials ongoing. Corcept’s pipeline candidates will face rivals, and there is no guarantee of market adoption even if they clear regulatory hurdles.

– Financial Execution Risks: Rapid changes in revenue trajectory can strain a company’s finances. Corcept’s cost base – including a growing R&D budget – was built on rising Korlym sales. If sales decline, Corcept might have to cut expenses or burn cash reserves to maintain its development programs. The company’s decision to pour cash into share repurchases at peak prices could be second-guessed if cash becomes tight. So far Corcept maintains healthy cash levels and no debt, but missteps (e.g. an overpriced acquisition attempt to fill the pipeline, or failure to curtail costs in a downturn) could weaken its financial position. Additionally, the class action and any settlement could cost money or higher D&O insurance premiums. Investors should watch for any guidance cuts or margin erosion in upcoming quarters as early signals of financial stress.

In sum, the red flags around Corcept include management credibility issues, a collapsing moat around its core product, and high-stakes pipeline bets. These translate into elevated risk that the company’s future performance may disappoint if management cannot navigate the post-Korlym landscape effectively.

Open Questions & Outlook

The developments at Corcept leave several open questions that will determine the company’s trajectory:

– Can relacorilant be salvaged for Cushing’s? A crucial unknown is whether Corcept will conduct additional trials or analyses to address the FDA’s concerns on relacorilant for hypercortisolism. The FDA deemed the evidence insufficient (www.prnewswire.com) – will the company design a new Phase 3 trial (perhaps with a placebo control or different endpoints) to try again? This would require significant time and investment, with no guarantee of success. Alternatively, Corcept might deprioritize relacorilant in Cushing’s and focus on other uses. How Corcept plans to respond to the CRL – and whether it can eventually bring relacorilant to market for Cushing’s – remains an open question.

– What will the FDA decide on relacorilant’s ovarian cancer indication? By mid-2026, the FDA is set to rule on relacorilant for platinum-resistant ovarian cancer (ir.corcept.com). The NDA is backed by positive Phase 3 data, but after one rejection, investors may be nervous. Approval would provide Corcept a fresh revenue stream and a validation of its cortisol-modulator approach in oncology. Conversely, another FDA rejection (or a requirement for more data) would be a serious setback to confidence. The outcome of this PDUFA event will heavily influence Corcept’s near-term outlook.

– How fast and deep will Korlym’s revenues decline? Now that the patent litigation is essentially over in favor of generics (www.sec.gov), a key unknown is the pace at which Korlym sales will fall. Will Corcept manage to retain a substantial share of the market through its distribution channels and perhaps price cuts? Or will payors rapidly switch Cushing’s patients to cheaper generic mifepristone, causing Korlym’s sales to crater in 2026–2027? The guidance Corcept provides (and its ability to meet it) in upcoming earnings reports will shed light here. This question is central to valuing the stock: a slower erosion buys Corcept more time (and cash) to support the pipeline, whereas a sharp drop could force strategic shifts (like cost cuts or even exploring a sale of the company).

– What is the endgame for the class action and investigations? The shareholder lawsuit raises concerns about what information was exchanged “behind closed doors” with FDA (www.prnewswire.com) (www.prnewswire.com). Discovery in this case could reveal internal documents or communications that either substantiate or refute the claims of concealment. An open question is whether Corcept will fight the allegations in court or seek an early settlement to limit damage. Additionally, Hagens Berman’s involvement and calls for whistleblowers (www.prnewswire.com) hint at the possibility of broader regulatory scrutiny – it’s unclear if the SEC or DOJ might look into Corcept’s disclosures. The resolution of these legal matters will influence investor sentiment and could impose financial costs; it’s a storyline to monitor through 2026.

– Can Corcept successfully pivot its business model? Strategically, Corcept now must transition from a one-product company to a multi-product one. The cortisol modulation platform it touts has potential applications in oncology, metabolic and neurologic disorders (ir.corcept.com). The company’s long-term success will depend on advancing new indications to market before Korlym’s cash cow dries up. This raises questions: Will Corcept’s next wave of trials (e.g. for miricorilant in NASH or other candidates) yield compelling results? Can the company leverage its scientific expertise to stay ahead of competitors in new domains? Or, given the challenges, is Corcept a takeover candidate for a larger pharma looking to acquire its cortisol-modulator portfolio? The coming 12–18 months – as clinical data read out and as management outlines a post-Korlym game plan – should provide answers.

Outlook: In the near term, Corcept’s stock will likely remain under pressure and volatile as these questions play out. Investors will be looking for management to restore confidence – perhaps via clear plans for relacorilant, disciplined financial management, and transparent communication. Positive surprises (e.g. an FDA approval for ovarian cancer, slower Korlym decline, or a legal win) could stabilize the story, whereas further disappointments (another trial failure or weak guidance) would compound the downside. CORT’s situation is an acute example of biotech risk: scientific setbacks can rapidly cascade into legal and financial troubles. How the company navigates this storm will determine whether the current panic is a temporary setback or part of a longer decline. For now, caution is warranted, and close attention to upcoming FDA decisions and earnings updates is advised as we await clarity on Corcept’s path forward.

Sources: Corcept 10-K filings (www.sec.gov) (www.sec.gov) (www.sec.gov); Corcept press releases and SEC filings (www.sec.gov) (ir.corcept.com); Hagens Berman class action alert (www.prnewswire.com) (www.prnewswire.com); BriefGlance analyst summary (briefglance.com) (briefglance.com).

For informational purposes only; not investment advice.